BMEA

Biomea Fusion, Inc.

Healthcare
Biotechnology
$126M market cap

Forecast run · Sep 14, 2026Upside rank 368 of 3,136

Model Signal

ForecastQ Daily Probabilities

59.7%

57.0%

42.4%

Analyst Consensus

Recommendation2.23/5 Buy

Last price$1.74

Price target$20.20

Implied move+1060.9%

Analysts13

ForecastQ Portfolios

BMEA is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.